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Central nervous system histoplasmosis
Multicenter retrospective study on clinical features, diagnostic
approach and outcome of treatment
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Abstract
Central nervous system (CNS) involvement occurs in 5 to 10% of individuals with disseminated histoplasmosis. Most experience has
been derived from small single center case series, or case report literature reviews. Therefore, a larger study of central nervous
system (CNS) histoplasmosis is needed in order to guide the approach to diagnosis, and treatment.
A convenience sample of 77 patients with histoplasmosis infection of the CNS was evaluated. Data was collected that focused on
recognition of infection, diagnostic techniques, and outcomes of treatment.
Twenty nine percent of patients were not immunosuppressed.Histoplasma antigen, or anti-Histoplasma antibodies were detected
in the cerebrospinal fluid (CSF) in 75% of patients. One year survival was 75% among patients treated initially with amphotericin B,
and was highest with liposomal, or deoxycholate formulations. Mortality was higher in immunocompromised patients, and patients
54 years of age, or older. Six percent of patients relapsed, all of whom had the acquired immunodeficiency syndrome (AIDS), and
were poorly adherent with treatment.
While CNS histoplasmosis occurred most often in immunocompromised individuals, a significant proportion of patients were
previously, healthy. The diagnosis can be established by antigen, and antibody testing of the CSF, and serum, and antigen testing of
the urine in most patients. Treatment with liposomal amphotericin B (AMB-L) for at least 1 month; followed by itraconazole for at least
1 year, results in survival among the majority of individuals. Patients should be followed for relapse for at least 1 year, after stopping
therapy.
Editor: Kwang Sik Kim.
Summary of Study: Histoplasmosis of the central nervous system (CNS) is a rare disease. While most patients are immunocompromised, or of advanced age, some
are otherwise healthy. Diagnosis can be established by serologic testing for antigen, or antibody in the majority of patients. Treatment with liposomal amphotericin B
(AMB-L) followed by itraconazole is recommended, but mortality remains high in immunocompromised patients, and those of advanced age. Relapse is uncommon in
patients who are adherent to therapy.
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Abbreviations: AIDS=Acquired immunodeficiency syndrome, CF=Complement fixation, CNS= central nervous system, CSF=
Cerebrospinal fluid, CT = computerized tomography, IDSA = Infectious Disease Society of America, MRI = magnetic resonance
imaging.
Keywords: antibody, antigen, brain, diagnosis, histoplasma, histoplasmosis, meningitis, outcome, treatment
1. Introduction
CNS infection occurs in 5 to 10% of patients with disseminated
histoplasmosis.[1] The recognition, diagnosis, and treatment of
CNS histoplasmosis is not well-characterized. The clinical
features, appropriate diagnostic testing, and treatment regi-
mens recommended for the evaluation, and management of
CNS histoplasmosis are based on case reports, and small case
series of patients.[1–3] These studies have demonstrated that the
most common clinical features of CNS histoplasmosis consist of
chronic meningitis,[4] focal brain, or spinal cord lesions, stroke
syndromes, encephalitis, and hydrocephalus.[5] Over one third
of cases reported, have occurred in immunocompetent
individuals.[1,2]
Morbidity, and mortality appear to be high in patients with
CNS histoplasmosis with high rates of relapse.[1] Despite
prolonged courses of treatment, the case fatality was 39%with
half of the survivors relapsing in a prior study.[1] Among AIDS
patients with CNS histoplasmosis, 3 of 5 patients died, and 1
relapsed despite treatment with deoxycholate amphotericin B
(AMB-D) followed by fluconazole, or itraconazole.[3] Although
adherence appears to have been suboptimal in that study,[3] this
experience shows that the outcome may be poor in some
patients.
The diagnosis is often delayed because of failure to consider
histoplasmosis in cases of chronic meningitis in which routine
cultures are negative. Unfamiliarity with the tests used for
diagnosis of histoplasmosis in this setting may also contribute to
delayed diagnosis. Histoplasma can be isolated from fungal
culture of Cerebrospinal fluid (CSF) in only 1 quarter of patients,
and visualization of yeast is rare.[1,2] An example of the difficulty
in diagnosis is provided by a case in which CSF cultures were
negative on 2 occasions 5 years apart but positive 2 years later,
when 30ml of CSF was cultured.[6]
The most sensitive method for diagnosis of CNS histoplasmo-
sis, based on evidence from the largest single institution series,[1]
includes use of tests for detection of antibody, and antigen in the
CSF.[5] Anti-Histoplasma antibodies were detected in the CSF by
immunodiffusion (ID) or complement fixation (CF) in 50% of
patients in one series,[1] and as many as 90% of patients in
another study.[2]
The Infectious Disease Society of America (IDSA)[7] guideline
for treatment of CNS histoplasmosis recommends an initial
course of AMB-L followed by itraconazole for at least 1 year.[7]
That recommendation was based upon improved survival, and
clinical response in AIDS patients with disseminated histoplas-
mosis treated with AMB-L rather than with AMB-D.[8] These
findings, coupled with poor outcome of CNS histoplasmosis[1]
formed the basis for the IDSA guideline recommendation.
The objectives of this study were to expand our knowledge of
the clinical manifestations, approach to diagnosis, and treatment,
and outcome of CNS histoplasmosis, based on a retrospective
multicenter review of the largest number of cases of CNS
histoplasmosis studied to date, which weremostly, managed after
publication of the IDSA guidelines.
2. Methods
Study design: This is a retrospective multicenter study of cases
occurring mostly, between 1997 and 2010 (74 of 77 patients) in
which physicians were surveyed for cases of CNS histoplasmosis.
Patients were sought from investigators who participated in
recent studies,[9–12] or who corresponded with one of the authors
(L.J.W.) for advice about diagnosis, or management. This group
of patients was obtained from a convenience sample which may
lead to selection bias. A standardized case report form was used
for data collection, which included information about underlying
conditions, clinical manifestations, diagnostic testing, and
outcome of therapy. The study was approved by the institutional
review board at the institutions of each of the collaborating
investigators. Disease severity was classified as mild if the patient
was managed without hospitalization, moderate if the patient
was hospitalized, and severe if the patient required critical care
unit admission. Functional impairment was classified as none,
mild (no limitation activity), moderate (slight limitation activity),
and severe (unable to work, attend school, or manage
household).
A proven diagnosis was achieved by isolation ofHistoplasma
from fungal culture, or visualization of appropriate morpho-
logic fungal forms in the CSF, brain, or spinal cord tissue.
A probable diagnosis required a positive antigen, or antibody
test from CSF. A possible diagnosis required laboratory
confirmation of pulmonary, or disseminated histoplasmosis
without another cause for CNS disease, based upon clinical
findings including symptoms, and examination, in the
absence of laboratory criteria for proven, or probable CNS
histoplasmosis.
2.1. Statistical analysis
Chi-squared analysis was used to compare subgroups using
MedCalc software (Acacialaan 22,8400 Ostend, Belgium). P-
values< .05 were considered significant. A multivariable
logistic regression model for the outcome of death within 12
months was determined by stepwise selection, with P-value
entry, and stay criteria of P< .2. Variables noted to be
associated with mortality within 12 months with P< .2 in
univariable analysis were included in the finalmodel. To control
for the effect of age, and disease severity on the outcome, those
variables were also incorporated for the final model. Akaike
Information Criteria, likelihood ratio test, and area under the
receiver operating characteristic curve were used to select the
models with the most optimal fitness. Missing data were
excluded from the analysis.
Mortality at 12 months was compared across underlying
conditions, baseline severity, and between amphotericin B
treatment types using Fisher’s exact tests. Additionally, time to
deathwas assessed between amphotericin B treatment types using
Kaplan-Meier product limit estimates and the log-rank test.
Analyses were performed using R (version 3.3.2) (R Foundation
for Statistical Computing, Vienna, Austria).
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3. Results
3.1. Demographics
The demographic characteristics are presented in Table 1. A total
of 77 patients were identified by the authors at their respective
institutions. Seventy one percent of patients were immunocom-
promised, and 13%were over 54 years of age. Sixteen percent of
infections occurred in otherwise healthy individuals less than 55
years old.
3.2. Clinical findings
Clinical features are presented in Table 2. CNS disease was the
initial manifestation of histoplasmosis in 84% of patients, and a
relapse of disseminated histoplasmosis occurred in 16%.
Presentation as a relapse occurred more often in AIDS patients
(9 relapses among 34 patients with AIDS, 26%) than in others (4
relapses among 43 patients with conditions other than AIDS,
9%), P= .09. Symptoms had been present for 2 weeks or less in
35% of patients, and more than 26 weeks in 12%.
3.3. CSF findings
CSF findings are summarized in Table 3 and were available from
72 out of the 77 patients identified. Most patients (50%) were
found to have a lymphocytic pleocytosis, 11% presented with a
neutrophilic pleocytosis, and one third of patients had less than 5
cells/mL. No CSF abnormality was noted in 12 patients. Brain, or
spinal cord imaging that was performed in 11 of these 12 patients
exhibited changes consistent with CNS histoplasmosis in 9,
leaving 2with no CSF, or imaging abnormalities by computerized
tomography (CT) scan. In these 2 patients, the clues to diagnosis
were based on CNS symptoms, and examination supported by
positive antigen, or culture of the CSF. Confusion, and impaired
mentation were prominent in an AIDS patient in whom the CSF
antigen was 5.3ng/ml in 1 of these 2 patients, and headache was a
major complaint in the other, a renal transplant patient in whom
the CSF culture was positive.
3.4. Imaging findings
Brain imaging was abnormal in 72% of patients (n=76)
(Table 4). Magnetic resonance imaging (MRI) detected lesions
that were not observed on CT in 4 patients (5%). Focal mass
lesions were the most commonly observed abnormality seen in
20% of patients. Less common lesions identified in 1 patient each
included diffuse white matter changes, areas of restricted
diffusion, low density lesions in the cerebellum, subdural
hematoma, and focal mass lesions. Spinal cord lesions included
enhancement in 3, non-mass lesions in 3, and disc protrusionwith
cord compression, and bone lesions in 1 patient each.
3.5. Diagnostic findings
Diagnosis was established within 2 weeks of presentation in 28%
of patients, and more than 26 weeks after presentation in 27%
(Table 2). The time to diagnosis was more than 26 weeks in 50%
Table 1
Assessment of demographic characteristics, and underlying
conditions, or age in 77 patients.
Parameter Number (percent)
Gender
Male 48 (62%)
Female 29 (38%)
Race or ethnicity
Caucasian 42 (55%)
African American 23 (30%)
Hispanic 9 (12%)
Pacific Islander 1 (1%)
Unknown 2 (3%)
Underlying conditions and age
AIDS 34 (44%)
Transplantation 10 (13%)
Other immunocompromise 11 (14%)
Age >54 years 10 (13%)
None 12 (16%)
AIDS=Acquired immunodeficiency syndrome.
Table 2
Clinical findings, duration of CNS symptoms, and time interval
between initial presentation, and diagnosis of CNS histoplasmosis.
Parameter Number (%)
CNS symptoms (N=77)
Any 66 (86%)
Headache 46 (60%)
Confusion 27 (35%)
Neck stiffness 13 (17%)
Ataxia 6 (8%)
Weakness 5 (6%)
Visual complaints 9 (12%)
CNS signs (N=77)
Altered mental status 32 (42%)
Focal deficit 23 (30%)
Neck rigidity 10 (13%)
Visual impairment 7 (9%)
Seizure 5 (7%)
Duration CNS symptoms (N=72)
Less than one week 19 (26%)
1 to 2 weeks 6 (8%)
2 to 4 weeks 17 (24%)
5 to 26 weeks 21 (29%)
More than 26 weeks 9 (12%)
Time between presentation and diagnosis (N=64)
Less than one week 7 (11%)
1 to 2 weeks 11 (17%)
2 to 4 weeks 9 (14%)
5 to 26 weeks 20 (31%)
More than 26 weeks 17 (27%)
CNS= central nervous system.
Table 3
Summary of CSF findings.
Parameter Median (range) Number/total (%)
Leukocyte count >5 cells/ml 85.5 (6–4450) 48/72 (66%)
Lymphocytic pleocytosis
∗
77% (12–100%) 36/72 (50%)
Neutrophilic pleocytosis† 67% (52–86%) 8/72 (11%)
Unknown differential Not applicable 4/72 (5%)
Leukocyte count < 5 cells/ml 1 (0–3) 24/72 (33%)
Protein >50mg/dl 102 (17–925) 55/71 (77%)
Glucose <40mg/dl 38 (6–187) 37/70 (53%)
Any CSF abnormality Not applicable 60/72 (83%)
No CSF abnormality Not applicable 12/72 (17%)
CSF=Cerebrospinal fluid
∗
Defined as a predominance of CSF lymphocytes compared with other leukocyte types.
† Defined as a predominance of CSF neutrophils compared with other leukocyte types.
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of non-immunocompromised patients, and 12% of immuno-
compromised patients. Failure to suspect histoplasmosis lead to
delays in diagnosis in 9 patients (12%). Four patients were
erroneously treated for presumed tuberculosis before histoplas-
mosis was diagnosed. Other misdiagnoses included neuro-
sarcoidosis in 2 patients, toxoplasmosis, multiple sclerosis, and
Behcet’s syndrome in 1 patient each. Four of these five patients
were treated with corticosteroids. Another patient who had a
history of pulmonary histoplasmosis was misdiagnosed as having
CNS lymphoma.However,H. capsulatumwas isolated fromCSF
following the patient’s death.
Results of diagnostic tests are summarized in Table 5.
Detection of antigen in the CSF was the most common method
for diagnosis. Antigen (n=53) was detected more often in
immunocompromised than in non-immunocompromised
patients, and in those with severe disease. Antibody detection
by ID, or CF (n=32) was the next most common method for
diagnosis, with similar findings in immunocompromised, and
non-immunocompromised patients, and with severe, and non-
severe disease. The antibody test was positive more often than the
antigen test in non-immunocompromised patients. The highest
diagnostic yield was achieved by testing the CSF for antigen, and
anti-Histoplasma antibody (n=57). At least 1 of these 2 tests was
positive in 3 quarters of patients overall, including 85% of
immunocompromised, and 56% of non-immunocompromised
patients. Among all patients, antigen was detected in the urine in
44 of 60 (73%) patients, and in the serum in 14 of 28 (50%) that
were tested. Anti-Histoplasma antibodies were detected in the
serum in 22 of 37 patients (59%), including 14 of 32 (44%) by
ID, and 22 of 35 (63%) by CF.
Histoplasma was isolated from culture of CSF, or yeast
resembling H. capsulatum were observed in brain tissue
histopathology, or in CSF in 38% of patients (n=69) (Table 5).
The initial CSF culture was negative but a subsequent culture was
positive in 5 patients. Culture of CSF was negative with a positive
culture of brain tissue in 2 patients. Histopathology of brain
tissue was positive but culture of CSF was negative in 2 patients.
Culture, or histopathology of the brain was positive in 3 patients
with negative cultures from CSF.
The etiology of CNS disease was not definitively established by
pathology, culture, or serology in 22% of patients (17 of 77
patients). These were classified as casesof “possible” CNS
histoplasmosis. They were typically characterized as patients
with pulmonary, or disseminated histoplasmosis who had
meningitis, or CNS signs, or symptoms with brain imaging
abnormalities without another etiology identified. Pathology,
and/or culture of CSF, or tissue were negative in 16 of these
patients. Tests for antigen, or antibody in the CSF were negative
in 9, and not performed in 8 patients. Detection of antigen, or
antibody in the urine, or serum provided laboratory basis for
diagnosis of histoplasmosis in 16 of the possible cases.
Disseminated histoplasmosis was previously, diagnosed in the
17th patient.
3.6. Outcome of treatment
Patient characteristics associated with survival for at least 12
months are summarized in Table 6. The risk for death increased
with age, management in an intensive care unit (ICU), and
duration of amphotericin B treatment, but these differences were
not statistically, significant. Survival was assessed in 58 patients
who were treated initially, with an amphotericin B formulation,
and followed for at least 1 year. The median follow-up in patients
who survived at least 1 year was 26 months. Survival was not
impacted by underlying condition, or the severity of illness
(Table 7).
One year survival was higher in patients treated with
deoxycholate (13 of 16, 81.2%), or AMB-L (21 of 26, 80.8%)
thanwith amphotericin B lipid complex (9 of 16, 56.2%), P= .20.
There was a trend for improved survival when patients treated
with deoxycholate, or liposomal formulations of amphotericin B
Table 4
CT or MRI of the brain in 76 patients.
Finding
∗
Number (%)
No abnormalities† 21 (28%)
Mass lesion 15 (20%)
Multiple abnormalities 13 (17%)
Ventricular enlargement 7 (9%)
Meningeal enhancement 6 (8%)
Other 6 (8%)
T2/flair signal abnormalities 5 (7%)
Infarcts 2 (3%)
CT= computerized tomography, MRI=magnetic resonance imaging.
∗
The findings are based on CT scan in 21, and MRI in 55 of the patients.
† No MRI was performed in 8 of 21 patients with no abnormalities.
Table 5
Correlation of the sensitivity of diagnostic tests performed on CSF with immunosuppression, and disease severity.
Immuno-compromised, n=55
∗
Not immuno-compromised, n=22
∗
Total P value
Culture or pathology 19/48, 40%† 7/21, 33% 26/69, 38% .778
Antigen 30/37, 81% 5/16, 31% 35/53, 66% .001
Antibody4 12/19, 63% 7/13, 54% 19/32, 59% .922
Antigen or antibody 33/39, 85% 10/18, 56% 43/57, 75% .041
Severe3, n=23
∗
Not severe3, n=54
∗
Total P value3
Culture or pathology 9/20, 45% 17/49, 35% 26/69, 38% .615
Antigen 14/15, 93% 21/38, 55% 35/53, 66% .021
Antibody4 3/6, 50% 16/26, 62% 19/32, 59% .937
Antigen or antibody 14/15, 93% 29/42, 69% 43/57, 75% .133
CSF=Cerebrospinal fluid.
∗
The number in the table headings represent total number of patients in these groups but not all patients had tests performed, explaining why they do not agree with the numbers compared in the tables.
† Positive/total, percent positive.
3Comparison of results in severe (ICU admission, n=23), and not severe cases, which combines mild (none hospitalized, n=6), or moderate (hospitalized, non-ICU, n=48).
4Immunodiffusion, or complement fixation.
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were grouped together, and compared with those treated with
amphotericin B lipid complex (Table 7), P= .09. The mean
survival time during the 1st year of follow-up was longer in
patients treated with deoxycholate, or AMB-L than in patients
treated with amphotericin B lipid complex, P= .040 (Fig. 1).
Serial CT, or MRI imaging, or the brain cord was performed in
22 patients, and the findings are described in a supplemental
table, http://links.lww.com/MD/C177.
Eleven patients were treated initially with a triazole (itraco-
nazole, 6; voriconazole, 5), 4 of whom died during the first month
of therapy (itraconazole, 2; voriconazole, 2). Mortality was
similar in patients treated initially, with a triazole, and with any
amphotericin B formulation (Table 6).
Nine patients died more than 1 year after diagnosis. Two were
attributed to histoplasmosis, occurring at 16 and 18 months after
diagnosis. Both were patients with AIDS who were poorly,
adherent to antifungal therapy.
Relapse occurred in 3 of 49 (6%) patients with follow-up of at
least 1 year (median, 21 months). The 3 relapses occurred among
21 patients with CNS histoplasmosis who had AIDS, at 18, 29,
and 57 months of follow-up, during continued therapy with
itraconazole, or fluconazole. These patients were considered to
have been non-adherent to therapy.
Functional status was determined in 44 patients who survived
for more than 1 year (median, 26 months). Fifty-four percent
exhibited no functional impairment, 14% were mildly impaired,
18% moderately impaired, and 14% were severely impaired.
Severe impairment occurred in 5 of 29 (17%) immunocompro-
mised, and 1 of 15 (6%) non-immunocompromised patients,
P= .58. Functional status at initial presentation was not recorded,
precluding assessment of change in functional status.
4. Discussion
This is the largest study of CNS histoplasmosis yet performed,
expanding our knowledge regarding clinical presentation,
diagnosis, and outcomes, complementing prior case series.[1–3]
Some important, but frequently overlooked findings include the
fact that CNS histoplasmosis is not restricted to immunocom-
promised individuals, often presents as an acute illness, and
rarely, is rapidly, progressive. Diagnosis remains difficult, and
often delayed, especially in non-immunocompromised patients,
largely, because of failure to consider, and test for histoplasmosis,
and lack of awareness of the importance of antigen, and antibody
testing. Treatment according to IDSA guidelines[7] is highly
effective, but mortality, and morbidity remain high in immuno-
compromised patients, particularly those with AIDS who are
poorly, adherent to therapy.
Table 7
Factors associated with death in patients treated with amphoter-
icin B.
Parameter Number Death Number (%) P value
Underlying condition .608
AIDS 28 9 (32.1%)
Other immunocompromise 12 3 (25.0%)
Age >54 8 2 (25.0%)
None 10 1 (10.0%)
Baseline Severity .300
Mild 4 1 (25.0%)
Moderate 36 7 (19.4%)
Severe 18 7 (38.9%)
Treatment .091
AMB-D or L 42 8 (19.0%)
AMB-LC 16 7 (43.8%)
AIDS=Acquired immunodeficiency syndrome, AMB-D=deoxycholate amphotericin B, AMB-L=
liposomal amphotericin B, AMB-LC= lipid complex amphotericin B.
Figure 1. Twelve month survival in patients treated with AMB-D, or AMB-L
compared to AMB-LC. The mean survival time (standard error) during the 1
year of followup was 10.6 months (0.5 months) in patients treated with AMB-D,
or AMB-L, and 8.3 months (1.1 months) in patients treated with amphotericin B
lipid complex, P= .040. Data are calculated as the restricted mean with an
upper limit of 12 months. This is the expected number of months, out of the first
12, that would be experienced by each group. AMB-D=deoxycholate
amphotericin B, AMB-L= liposomal amphotericin B, AMB-LC= lipid complex
amphotericin B.
Table 6
Factors associated with death within 12 months following
diagnosis.
Parameter Odds ratio (95% CI) P value
Male gender 0.61 (0.22, 1.73) .35
Race/ethnicity
African American vs Caucasian 1.40 (0.45, 4.37) .56
Hispanic vs Caucasian 0.91 (0.16, 5.13) .92
Other vs Caucasian 1.60 (0.13, 19.6) .71
Age (per year increase in mortality) 1.02 (0.99, 1.05) .18
CNS relapse of prior histoplasmosis 0.94 (0.23, 3.89) .93
Severity at initial presentation
(hospitalized vs intensive care unit)
0.33 (0.11, 1.01) .052
CSF parameter at initial presentation
Leukocyte count 0.999 (0.998, 1.001) .57
Protein 0.998 (0.994, 1.003) .45
Glucose 0.99 (0.96, 1.01) .31
Histoplasma antigen concentration 1.01 (0.94, 1.09) .73
Treatment at initial presentation
Triazole vs amphotericin B 0.94 (0.26, 3.33) .92
Amphotericin B ≥ 28 days (yes vs no) 0.49 (0.17, 1.39) .18
CNS= central nervous system, CSF=Cerebrospinal fluid.
Multivariate analysis (performed if univariate P value< .20): age, P= .08; severity, P= .05;
amphotericin B≥28 days, P= .19.
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Histoplasmosis should be considered in the evaluation of
patients with chronic lymphocytic meningitis, and may be
overlooked in patients with acute disease, or predominantly
neutrophilic pleocytosis. The absence of immunocompromise
should not be a deterrent for testing for histoplasmosis as a cause
for chronic meningitis as well as a variety of other CNS syndromes
in patients who reside in endemic areas. Rarely, otherwise healthy
patientswith disseminated histoplasmosis have been found to have
specific defects in cellular immunity that may not be apparent on
initial evaluation.[13,14] CNS symptoms had been present for less
than 1month in over one half of patients, and for 1week, or less in
one quarter of patients in our case series, findings that are
uncharacteristic of chronic meningitis.[4] Some patients had been
treated for hydrocephalus for years without consideration of
fungal meningitis as the etiology. The clinical findings of CNS
histoplasmosis are often subtle, and not necessarily characteristic
of an infectious process. Forty-two percent of patients in our series
were afebrile. Headache, and confusion were the most common
complaints, and altered mental status was the most common
physical finding. Further complicating the diagnosis for this
infection, the CSF profile was normal in nearly 20% of patients,
and imaging of the brain was normal in over 1 quarter. The
diagnosis was not established within the first 2 weeks of
presentation in nearly, two-thirds of cases. Tuberculosis, and
noninfectious, inflammatorydisorders, includingneurosarcoidosis
were thought to be the cause of chronic meningitis thus leading to
inappropriatemanagement, and delays in therapy.Histoplasmosis
infection of the CNS should be considered in patients who reside in
endemic areas with otherwise unexplained acute sub-acute, or
chronic neurological illness, including meningitis, mass lesions
suggesting malignancy, stroke syndromes suggesting vasculitis, or
embolic events, and hydrocephalus.
The diagnosis of CNS histoplasmosis can be established non-
invasively, in 1 week or less in most patients by antigen, and anti-
Histoplasma antibody testing of CSF, and serum, and antigen
detection in urine. Recent studies reported that detection of
antibodies in the CSF using a previously reported enzyme
immunoassay[15] further improved the sensitivity for diagnosis
over that achieved by the older methods used in this study.
Nevertheless, antigen detection, antibody detection, culture, and
pathology of CSF, or brain tissue may be non-diagnostic in some
patients. In 5 patients in whom antigen, or antibody testing was
not performed, the diagnosis was established by demonstration
of characteristic yeast in brain tissue. Culture of the CSF usually
does not provide a rapid diagnosis, as growth requires more than
2weeks in most patients, and up to 6 weeks in some. Brain biopsy
for histopathology, and culture may be required in patients in
whom delay for serologic testing is unacceptable, or a diagnosis
cannot be made via non-invasive means.
Patient outcome appears to be improved in this cohort
compared to earlier studies. One year survival in patients treated
with any amphotericin B formulation (deoxycholate, liposomal,
or lipid complex) was 74% (43 of 58), compared to 55% in a
review published in 1990.[1] In a review of more contemporary
papers published between 2011 and 2016 reporting outcome in
15 patients, 80% survived.[16–30] Others have reported in smaller
studies that 6 of 8 patients were successfully treated with AMB-D
followed by itraconazole.[31] In that study 1 patient died, and
another relapsed 3 times, but was successfully, treated after shunt
replacement.[31] More recently, of 4 AIDS patients treated
with amphotericin B lipid complex followed by itraconazole,
or fluconazole, 3 died, and 1 relapsed, all of whom were
non-adherent to therapy.[3] The IDSA treatment guideline
recommends initial treatment with AMB-L for 4 to 6 weeks
followed by itraconazole for at least 1 year.[7] Consistent with
these guidelines, we observed a trend towards increased survival,
and significantly longer survival time in patients treated with
liposomal, or AMB-D than with amphotericin B lipid complex.
Others havemade similar observations in an experimental animal
model of Candida albicans infection of the CNS.[32] Deoxy-
cholate, and AMB-L reduced the fungal burden in the brain more
completely than amphotericin B lipid complex, or amphotericin B
colloidal dispersion. Pharmacodynamic parameters, namely the
ratio of maximum plasma concentration, and area under the
curve to minimum inhibitory concentration of free amphotericin
B, and time during dosing level above the minimum inhibitory
concentration, correlated with clearance of the organism from
brain tissue.[32] These pharmacodynamic differences were
attributed to structural characteristics responsible for a shorter
half-life in the plasma, smaller area under the curve, and larger
volume of distribution of the lipid complex, and colloidal
dispersion formulations. None of the amphotericin B formula-
tions achieved quantifiable concentrations in the CSF but all
achieve quantifiable concentrations in the brain tissue. AMB-L
achieved the highest concentration in the brain, about 6-fold
higher than deoxycholate, or lipid complex amphotericin B
(AMB-LC), and 4-fold higher than amphotericin B colloidal
dispersion. Because of reduced toxicity,[33] superior pharmaco-
dynamic characteristics, and greater concentration in brain
tissue, as well as improved survival demonstrated in our study,
AMB-L is the treatment of choice for CNS histoplasmosis.
The best triazole for continued treatment after amphotericin B
induction therapy is uncertain. Theoretically, a triazole that
achieves therapeutic concentrations in CSFwould be best. Studies
in an experimental animal model of Histoplasma meningitis
demonstrated that fluconazole, which achieves excellent concen-
trations in the CSF, was inferior to itraconazole, which does not
achieve therapeutic levels in CSF.[34] Therefore, it appears that
despite inadequate CSF penetration, itraconazole remains the
triazole of choice for “step-down” therapy following initial
treatment with AMB -L in patients with CNS histoplasmosis
infection.
The risk for relapse appears to be lower than in previous
studies. Relapse occurred in 6% of surviving patients followed
for at least 1 year in this study compared to 50% in the earlier
study.[1] The 3 relapses all occurred in patients with AIDS who
were not adherent to therapy in the current study, confirming
recent reports in which non-adherence was a significant risk
factor for failure of treatment.[3,11]
Some insight was gained into functional status of patients who
survived following treatment for the infection in this study.
Functional status at last follow-up was normal in over half of
patients but severely impaired in 14%, occurring predominantly
in the immunocompromised group. Whether impaired function
was related to a higher burden of disease, or severity of CNS
infection, or other factors, most notably underlying immuno-
compromising condition, or comorbidities is unknown.
The limitations of retrospective studies must be recognized,
most notably selection bias, incomplete information, uncon-
trolled therapy, and inconsistent follow-up. This group of
patients was obtained from a convenience sample whichmay lead
to selection bias. The sensitivity for antigen detection in the CSF
may have been inflated by including patients for whom the
treating physician sought advice about diagnosis, and manage-
ment from one of the authors (L.J.W.). Use of antigen testing for
diagnosis is not readily, available outside of the US, and our
Wheat et al. Medicine (2018) 97:13 Medicine
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treatment recommendations may not be feasible in resource-
limited countries.
In conclusion, clinicians should have a low threshold for
considering histoplasmosis as a cause for meningitis, brain
lesions, vascular events, or hydrocephalus in immunocompro-
mised, and non-immunocompromised patients who reside in
endemic areas, and for whom an alternative diagnosis has not
been established. A diagnosis of CNS histoplasmosis can be
established in a timely manner by detection of antigen, or anti-
Histoplasma antibodies in the CSF. The current IDSA guide-
lines[7] that recommend treatment with AMB-L administered for
4 to 6 weeks followed by itraconazole for at least 1 year are
supported with this study. Although not specifically addressed in
this study, it is well known that itraconazole levels should be
carefully monitored, and maintained above 1mg/ml when
treating systemic fungal infections.[7] Although relapse was less
common in this study than in the earlier review,[1] some relapses
may have been missed because of the retrospective nature of the
study, and inconsistent length of follow-up. Therefore, it remains
important to document complete resolution of infection in
response to therapy to prevent relapse. This can be accomplished
by monitoring imaging, as well as antigen, and antibody levels in
serum, urine, and CSF. The risk of relapsed infection is likely to
be less when it has been confirmed that CSF antigen tests have
become negative at some point during treatment, the CSF
formula has normalized, and patients have received at least
12 months of therapy in total.
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